

Innovative Antibody Engineering: Novel technologies and preclinical and clinical outcomes

12:45–13:30, 3 March 2020
Room 342A, Palais des Congrès de Paris

- 12:45–12:50 Introduction
Prof. Giuseppe Curigliano (Chair)
- 12:50–13:10 Antibody engineering: Novel technologies, antibody drug
conjugates and mechanisms of action
Prof. Matthias Peipp
- 13:10–13:25 Emerging preclinical and clinical data with novel antibody
drug conjugates in various tumour types
Prof. Giuseppe Curigliano
- 13:25–13:30 Q&A, conclusions

